Tarsus to Acquire Alkeus in $450 Million Deal, Reports Strong Quarter and Half
IRVINE, Calif.—Tarsus Pharmaceuticals announced yesterday that it has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001),…
